Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages.
Melendez-Torres GJ, Armoiry X, Court R, Patterson J, Kan A, Auguste P, Madan J, Counsell C, Ciccarelli O, Clarke A. Melendez-Torres GJ, et al. BMC Neurol. 2018 Oct 3;18(1):162. doi: 10.1186/s12883-018-1162-9. BMC Neurol. 2018. PMID: 30285675 Free PMC article. Review.
Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ, Auguste P, Armoiry X, Maheswaran H, Court R, Madan J, Kan A, Lin S, Counsell C, Patterson J, Rodrigues J, Ciccarelli O, Fraser H, Clarke A. Melendez-Torres GJ, et al. Health Technol Assess. 2017 Sep;21(52):1-352. doi: 10.3310/hta21520. Health Technol Assess. 2017. PMID: 28914229 Free PMC article. Review.
Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.
Armoiry X, Kan A, Melendez-Torres GJ, Court R, Sutcliffe P, Auguste P, Madan J, Counsell C, Clarke A. Armoiry X, et al. J Neurol. 2018 May;265(5):999-1009. doi: 10.1007/s00415-018-8752-8. Epub 2018 Jan 22. J Neurol. 2018. PMID: 29356977 Free PMC article. Review.
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials.
Connock M, Armoiry X, Tsertsvadze A, Melendez-Torres GJ, Royle P, Andronis L, Clarke A. Connock M, et al. BMC Cancer. 2019 Apr 25;19(1):392. doi: 10.1186/s12885-019-5507-6. BMC Cancer. 2019. PMID: 31023244 Free PMC article.
251 results